Pharma Focus Europe

Cytovance Biologics and Alcami Collaborate to Offer Comprehensive Solutions for Biologics Development

Monday, December 11, 2023

Cytovance Biologics has recently unveiled a strategic partnership with Alcami Corporation, another Contract Development and Manufacturing Organization (CDMO), with the goal of expanding their capabilities in large molecule biologic manufacturing and sterile fill-finish services.

Cytovance specializes in overcoming challenges in development and manufacturing by refining unique processes to assist drug developers in reaching critical milestones. Axel Schleyer, Cytovance's Chief Commercial Officer (CCO), expressed enthusiasm about combining Alcami's expertise in liquid and lyophilization sterile filling, packaging, and labeling with Cytovance's bulk drug substance development and manufacturing services. Schleyer emphasized that the collaboration, rooted in shared cultures of quality and innovation, positions them well to support the development of life-changing drugs from early stages to commercial supply.

As the number of promising drug targets increases, many developers lacking internal manufacturing resources face obstacles in progressing to clinical trials. They rely on trusted CDMO partners like Cytovance and Alcami to assist in achieving future commercialization goals. The success of bringing complex and challenging products to market requires collaboration with experts boasting years of experience and a proven track record in transforming molecules into bulk drug substances and delivering them to patients.

With the integration of Alcami's sterile fill-finish capabilities and advanced manufacturing and filling lines, Cytovance customers now have the option to transition their bulk product to a verified cGMP (current Good Manufacturing Practice) partner for advanced clinical and commercial production and packaging. Alcami's offerings include formulation, release and stability testing, vial and syringe filling, and advanced cGMP biostorage, having already supported the successful launch of over 50 commercial products.

Both companies are actively coordinating manufacturing processes and quality systems. Alcami CEO William Humphries expressed pride in collaborating with Cytovance, highlighting their combined 77 years of serving the life science industry and their commitment to delivering high-quality fill-finish operations. This collaboration marks Cytovance's third publicly announced partnership of the year, following two international collaborations with custom microbial strain development providers.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva